VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Type 2 diabetes                                    │ Type 2 diabetes                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age 18 - 75 years                                  │ Age 18 - 75 years                                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anti-GAD antibodies negative (Glutamic Acid        │ Anti-GAD antibodies negative (Glutamic Acid        │     100 │
│ Decarboxylase)                                     │ Decarboxylase)                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HbA1c 8.0 - 10.5 %                                 │ HbA1c 8.0 - 10.5 %                                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BMI 25.0 - 45.0 kg/m2                              │ BMI 25.0 - 45.0 kg/m2                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous therapy with BBIT (basal insulin and at   │ Previous therapy with BBIT (basal insulin and at   │     100 │
│ least once daily bolus insulin)                    │ least once daily bolus insulin)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any oral antidiabetic treatment except for  │ Use of any oral antidiabetic treatment except for  │     100 │
│ metformin (i.e., sulphonylureas, DPP-IV            │ metformin (i.e., sulphonylureas, DPP-IV            │         │
│ inhibitors, thiazolidinediones, SGLT-2 inhibitors  │ inhibitors, thiazolidinediones, SGLT-2 inhibitors  │         │
│ (Sodium dependent glucose transporter) or GLP-1    │ (Sodium dependent glucose transporter) or GLP-1    │         │
│ analogues (glucagone like peptide) within the last │ analogues (glucagone like peptide) within the last │         │
│ three months prior to Screening                    │ three months prior to Screening                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Repeated episodes of severe hypoglycaemia within   │ Repeated episodes of severe hypoglycaemia within   │     100 │
│ the last six months prior to Screening             │ the last six months prior to Screening             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of diabetic ketoacidosis, precoma          │ History of diabetic ketoacidosis, precoma          │     100 │
│ diabetica, or diabetic coma                        │ diabetica, or diabetic coma                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with any other investigational drug      │ Treatment with any other investigational drug      │     100 │
│ within the last three months before Screening      │ within the last three months before Screening      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute infections within the last four weeks prior  │ Acute infections within the last four weeks prior  │     100 │
│ to Screening                                       │ to Screening                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recurrent urogenital infections                    │ Recurrent urogenital infections                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of pancreatitis                            │ History of pancreatitis                            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anamnestic history of hypersensitivity to the      │ Anamnestic history of hypersensitivity to the      │     100 │
│ study drugs or to drugs with similar chemical      │ study drugs or to drugs with similar chemical      │         │
│ structures                                         │ structures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of severe or multiple allergies            │ History of severe or multiple allergies            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant participation in other clinical trials │ Concomitant participation in other clinical trials │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Type 1 diabetes                                    │ Type 1 diabetes                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Cardiovascular disease Clinically relevant         │ Cardiovascular disease Clinically relevant         │     100 │
│ ventricular tachycardia or ventricular             │ ventricular tachycardia or ventricular             │         │
│ fibrillation, 3rd degree AV block or Torsades de   │ fibrillation, 3rd degree AV block or Torsades de   │         │
│ Pointes or treatment with antiarrhythmic drugs.    │ Pointes or treatment with antiarrhythmic drugs.    │         │
│ Percutaneous coronary intervention within the past │ Percutaneous coronary intervention within the past │         │
│ 6 months. Any of the following within the past 6   │ 6 months. Any of the following within the past 6   │         │
│ months: myocardial infarction (MI), coronary       │ months: myocardial infarction (MI), coronary       │         │
│ artery bypass surgery; unstable angina; or stroke  │ artery bypass surgery; unstable angina; or stroke  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Malignancy including leukemia and lymphoma within  │ Malignancy including leukemia and lymphoma within  │     100 │
│ the last 5y                                        │ the last 5y                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver disease such as cirrhosis or chronic active  │ Liver disease such as cirrhosis or chronic active  │     100 │
│ hepatitis                                          │ hepatitis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant renal dysfunction (see also exclusion  │ Significant renal dysfunction (see also exclusion  │     100 │
│ criteria laboratory abnormalities)                 │ criteria laboratory abnormalities)                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ State after kidney transplantation                 │ State after kidney transplantation                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Endocrine disease                                  │ Endocrine disease                                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Systolic blood pressure outside the range of       │ Systolic blood pressure outside the range of       │     100 │
│ 100-160 mmHg or diastolic blood pressure above 95  │ 100-160 mmHg or diastolic blood pressure above 95  │         │
│ mmHg at Screening                                  │ mmHg at Screening                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or childbearing potential without        │ Pregnancy or childbearing potential without        │     100 │
│ adequate contraception                             │ adequate contraception                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Present therapy with systemic steroids             │ Present therapy with systemic steroids             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Potentially unreliable subjects, and those judged  │ Potentially unreliable subjects, and those judged  │     100 │
│ by the investigator to be unsuitable for the study │ by the investigator to be unsuitable for the study │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindications for Magnetic resonance (MR)      │ Contraindications for Magnetic resonance (MR)      │     100 │
│ scanning such as persons with cardiac pacemaker    │ scanning such as persons with cardiac pacemaker    │         │
│ and implants out of metal or claustrophobia        │ and implants out of metal or claustrophobia        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ C-peptide levels ≥ 1.5 ng/mL                       │ C-peptide levels = 1.5 ng/mL                       │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fasting blood glucose \> 126 mg/dl                 │ Fasting blood glucose > 126 mg/dl                  │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of active substance abuse (including       │ History of active substance abuse (including       │      99 │
│ alcohol \> 40g/day) within the past 2 years        │ alcohol > 40g/day) within the past 2 years         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of psychiatric disorder or intake of      │ Presence of psychiatric disorder or intake of      │      99 │
│ anti-depressive or anti-psychotic agents with the  │ anti-depressive or anti-psychotic agents with the  │         │
│ exception of benzodiazepines and SSRIs/SNRI´s      │ exception of benzodiazepines and SSRIs/SNRI's      │         │
│ (selective serotonin reuptake inhibitor)           │ (selective serotonin reuptake inhibitor)           │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ •Any of the following significant laboratory       │ Presence of psychiatric disorder or intake of      │      36 │
│ abnormalities: eGFR (as calculated by the MDRD     │ anti-depressive or anti-psychotic agents with the  │         │
│ equation) \< 60 ml/min at Screening Fasting        │ exception of benzodiazepines and SSRIs/SNRI's      │         │
│ triglycerides \>700 mg/dl (\>7.9 mmol/l)           │ (selective serotonin reuptake inhibitor)           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Age 18 - 75 years                                  │      40 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled unstable angina pectoris or history   │ Cardiovascular disease Clinically relevant         │      40 │
│ of pericarditis, myocarditis, endocarditis.        │ ventricular tachycardia or ventricular             │         │
│ Congestive heart failure NYHA (New York Heart      │ fibrillation, 3rd degree AV block or Torsades de   │         │
│ Association) class III or IV. Increased risk of    │ Pointes or treatment with antiarrhythmic drugs.    │         │
│ thromboembolism, e.g. subjects with a history of   │ Percutaneous coronary intervention within the past │         │
│ deep leg vein thrombosis or family history of deep │ 6 months. Any of the following within the past 6   │         │
│ leg vein thrombosis, as judged by the Investigator │ months: myocardial infarction (MI), coronary       │         │
│                                                    │ artery bypass surgery; unstable angina; or stroke  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acromegaly or treatment with growth hormone or     │ Cardiovascular disease Clinically relevant         │      43 │
│ similar drugs. Chronic oral or parenteral          │ ventricular tachycardia or ventricular             │         │
│ corticosteroid treatment (\>7 consecutive days of  │ fibrillation, 3rd degree AV block or Torsades de   │         │
│ treatment) within 8 weeks; thyroid hormone         │ Pointes or treatment with antiarrhythmic drugs.    │         │
│ replacement is allowed if the dosage has been      │ Percutaneous coronary intervention within the past │         │
│ stable for at least 3 months and the TSH is within │ 6 months. Any of the following within the past 6   │         │
│ normal limits                                      │ months: myocardial infarction (MI), coronary       │         │
│                                                    │ artery bypass surgery; unstable angina; or stroke  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years                  │ Age 18 - 75 years                                  │      44 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 85
Average Levenshtein Ratio of individual lines: 91.78378378378379
OverAll Ratio: 88.3918918918919
